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Platelet Membrane and Calcium Control 
Abnormalities in Essential Hypertension 
F. R. Bühler and T. J. Resink 
The mechanisms whereby intracellular calcium concen­
tration is controlled are briefly reviewed. With the 
current knowledge of both calcium homeostasis and the 
function and properties of cellular Ca1^-target proteins/ 
signal transduction systems, a dysfunction of cellular 
calcium metabolism is considered in relation to the 
pathogenesis of hypertension. Although the enhanced 
peripheral vascular resistance characteristic of hyperten­
sion is ultimately a function of Ca2+ availability for 
smooth muscle cell contraction, the platelet possesses 
many parallel biochemical and physiologic properties. 
Therefore, we have utilized the platelet as the cell model 
for investigating the role of Ca2+ in hypertension dis­
orders. An overview of Ca2+-linked platelet processes al­
tered in essential hypertension is presented, and an 
attempt is made to integrate these multiple aberrations in 
a fundamental membrane lesion. Am J Hypertens 
1:42-46, 1988 
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Calcium is a fundamental regulator of cellular function. An understanding of the general principles of cellular C a 2 + regulation is crucial to the pathophysiology of hypertension and 
its effective treatment, because the heart, adrenal glo-
merulosa, neural synapses, juxtaglomerular apparatus, 
platelets, and smooth muscle cells use C a 2 + as a positive 
intracellular messenger. 
Intracellular calcium concentrations ([Ca 2 +]i) are reg­
ulated by a complex array of transport mechanisms at 
various membrane and intracellular locations. The entry 
of C a 2 + from the extracellular space is mediated by volt­
age-sensitive C a 2 + channels and other putative mecha­
nisms including release of C a 2 + bound to membrane 
surfaces, entry through receptor-mediated channels, or 
nondefined passive leak across the membrane. C a 2 + is 
also released from internal endoplasmic reticulum and 
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from mitochondria. In resting cells, [Ca 2 4 ^ is maintained 
at 10~ 7 M, that is, considerably lower than millimolar 
extracellular free C a 2 + . In stimulated cells, [Ca 2 +]i does 
not generally exceed 10~ 5 M. Therefore, under both 
conditions, internal calcium levels are necessarily main­
tained by the action of active transport mechanisms that 
remove C a 2 + from the cytosol, including the plasma 
membrane ATP-dependent C a 2 + pump, the plasma 
membrane N a + - C a 2 + exchanger, the endoplasmic re­
ticulum ATP-dependent Ca2"1" pump, and the mitochon­
dria C a 2 + pump. The net result of the operation of all 
these Ca 2 +-translocating mechanisms is the imbalance 
of C a 2 + concentrations within the cells, which are there­
fore primed for Ca 2 +-signaling events to permit a rapid 
and large increase incytosolic Ca2"1".1"3 
ESSENTIAL HYPERTENSION, PLATELETS, 
AND CALCIUM 
In the pathophysiology of essential hypertension (EHT), 
several factors have been proposed, including enhanced 
sympathetic nervous system activity, reduced renin-an­
giotensin-aldosterone axis endocrine control, dietary 
salt, and genetic factor(s). Direct clinical corollaries for 
an integrative contributory role for C a 2 + in the patho­
physiology of EHT are that patients with EHT exhibit 
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excess calcium-influx-dependent vasoconstriction and 
that blood pressure in these patients is normalized fol­
lowing therapy with calcium antagonists. 4" 6 A key 
characteristic of EHT is elevated peripheral vascular re­
sistance, which is ultimately mediated by enhanced vas­
cular contractility. An altered state of vascular reactivity 
can result from alterations in either cellular calcium me­
tabolism or the sensitivity of response elements to the 
actions of C a 2 + . 7 " 1 0 Investigations in search of support 
for the hypothesis that perturbation of calcium metabo­
lism is a fundamental lesion in EHT have been carried 
out on a wide variety of tissue and cell types including 
myocardium, smooth muscle, erythrocytes, adipocytes, 
hepatocytes, synaptosomes, and platelets in both 
human and animal models of hypertension. 7" 1 0 
A specific role for platelets in the pathophysiology of 
hypertension should be considered, because these cells 
are mediators of thrombotic complications, vectors for 
vascular tone, and promoters of atherosclerosis. There 
are many similarities between platelets and smooth 
muscle cells. Both platelets and smooth muscle cells 
have an adenylate cyclase system that can be activated 
by adrenaline via a-2 adrenoceptors and inhibited by 
prostaglandins with attendant changes in calcium. 1 1 
Calcium can be selectively stimulated via angiotensin II 
receptors,12 and calcium entry can be blocked by slow 
calcium channel inhibitors. 1 3 There are similar calcium-
dependent contractile systems and similar pools for reg­
ulation of intracellular calcium (the dense tubular sys­
tem in platelets and the sarcoplasmic reticulum in 
smooth muscle cells) . 1 2 There are comparable calcium-
dependent physiologic functions: shape change, aggre­
gation and secretion in platelets, and contraction in 
smooth muscle cells. Hormone-receptor activation leads 
to parallel alterations in the clinical setting of EHT: in­
creased sensitivity, shape change and aggregation of 
platelets, and increased vascular resistance of resistance 
vessels. These corollaries, together with easy clinical ac­
cessibility and preparative cellular homogeneity of 
platelets, focused our investigations on the human 
platelet as a model reflecting events occurring in smooth 
muscle cells. 
It is the purpose of this paper to present a summary of 
present findings with respect to cellular C a 2 + handling 
in platelets from patients with EHT in search of support 
for the hypothesis 7" 1 0 that a generalized membrane de­
fect is the common denominator underlying multiple 
Ca2 +-associated abnormalities in hypertension. Our 
own specific observations are summarized in Table 1. 
CYTOSOLIC FREE CALCIUM 
CONCENTRATIONS 
Intracellular calcium content has been demonstrated to 
be elevated in platelets, erythrocytes, and lymphocytes 
from patients with E H T . 7 " 1 0 ' 1 4 " 1 6 A correlation between 
platelet [ C a 2 + ] i and blood pressure has also been estab-
TABLE 1. PLATELET Ca2+-LINKED ABNORMALITIES 
IN ESSENTIAL HYPERTENSION 
System 
Directional 
Alteration Consequence 
Cytosolic free 
calcium 
Membrane poten­
tial 
(Ca2+-calmodu-
lin)-dependent 
ATPase 
Hormone 
(receptor) 
sensitivity 
Phosphoinositide 
metabolism 
Adenylate cyclase 
Increased 1 1 1 4 1 7 
Decreased21 
Capacity in­
creased but 
activation 
potential de­
creased24 
Increased43 
Phosphoinositide 
compositional 
equilibrium 
shifted toward 
polyphos­
phoinositide 
formation37 
Activity ratio 
(stimulated/ 
basal) increased 
Cell activation 
promoted 
C a 2 +
 influx 
increased 
Compensatory 
but inefficient 
stimulated Ca 2 + 
extrusion 
Potentiation of 
stimulation 
Potential for 
internal Ca 2 + 
release 
increased; 
modification of 
membrane-
associated pro­
cesses 
Compensatory 
A brief summary of our findings with respect to EHT and disorders of 
platelet systems that involve Ca2+. The directional nature of alterations is 
indicated, and other than proposed compensatory mechanisms, all modifi­
cations are considered to facilitate platelet shape change, aggregation, and 
secretion. Similar abnormalities may contribute to enhanced smooth mus­
cle contraction in EHT. 
lished. 1 4 Normalization of platelet [ C a 2 + ] i occurs follow­
ing antihypertensive therapy. 1 7 Whatever the underly­
ing mechanism, it is not entirely corrected by antihyper­
tensive therapy, because platelets from treated EHT pa­
tients still exhibit an amplified, stimulated [ C a 2 + ] i re­
sponse relative to control subjects. 1 7 These data imply 
an intrinsic cellular defect and possibly disturbed mech­
anisms, including membrane C a 2 + binding, C a 2 + influx, 
hormone-receptor transduction coupling, univalent cat­
ion transport, and C a 2 + efflux/sequestration. 7" 1 0 
MEMBRANE C a 2 + BINDING AND C a 2 + INFLUX 
Calcium binds to various components of the cell mem­
brane, including anionic phospholipids and proteins. 
Altered calcium handling is suggested by decreased 
C a 2 + binding to the inner and outer surface of plasma 
membranes of erythrocytes, adipocytes, and 
hepatocytes, 7" 1 0 perhaps due to a reduction in the num­
ber of Ca 2 +-binding sites (as opposed to an affinity alter­
ation). 1 8 Defective calcium binding has been proposed 
to favor depolarization with consequent activation of 
potential operated calcium channels. 8 While studies of 
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the function of potential dependent C a 2 + channels in 
hypertension are scarce, available data for synapto-
somes and platelets of S H R 1 9 , 2 0 and platelets of EHT 2 1 
indicate partial depolarization of plasma membranes. 
Such an abnormality could give rise to an increased 
basal C a 2 + influx and hence increased [ C a 2 ^ . 
PROTEIN Ca 2 + BINDING AND C a 2 + EFFLUX 
Cytoplasmic divalent cation-binding substances have 
also been considered in the pathogenesis of 
hypertension, 7" 1 0 but most of them (ie, glycerophos­
phates, nucleotides, and inorganic phosphates) are 
characterized by K D values that are two to three orders 
of magnitude larger than the range of possible changes 
in [ C a 2 + ] i . Rather, focus has been on the highly selective 
Ca 2 +-binding proteins (K D 10~ 6 to 10~ 8 M) such as cal­
modulin, which plays a central role in the Ca 2 +-depen-
dent regulation of eukaryotic cells. 2 2 In EHT, a modifica­
tion of interaction between calmodulin and its target 
proteins has been proposed. 7 1 0 Of the many target pro­
teins, the plasma membrane Ca 2 + -ATPase is of major 
interest because of its critical role in maintaining C a 2 + 
homeostasis via the promotion of C a 2 + efflux.23 The 
findings with respect to this efflux system in hyperten­
sion are somewhat varied, with reports of increased, 
decreased, or unaltered act ivi t ies . 7 , 2 4 - 2 8 The regulation 
of Ca 2 + -ATPase, however, is complex, and in addition 
to C a 2 + and calmodulin other factors such as membrane 
hydrophobicity, acidic phospholipids, polyphosphoin­
ositides, and proteolysis can modulate C a 2 + efflux 
activity. 7" 2 3 
PHOSPHOINOSITIDE METABOLISM 
Phosphoinositides may influence not only the plasma 
membrane but also internal membranes. Stimulated 
C a 2 + release from large stores in the endoplasmic reticu­
lum is believed to be mediated by inositol 1,4,5 tris-
phosphate, a product of hormone-activated phosphoin-
ositide hydrolysis. 3 0" 3 4 Phosphoinositide metabolism is 
also implicated in the regulation of C a 2 + influx/efflux 
via the plasma membrane, membrane fluidity, mem­
brane C a 2 + binding, and membrane Ca 2 + -ATPase and 
adenylate cyclase activities. 2 9" 3 3 θί
λ
-adrenoceptors are 
directly coupled to phosphoinositide turnover (as are 
vasopressin and angiotensin II receptors), while a2-
adrenoceptors are coupled to adenylate cyclase inhibi­
tion. 3 4 Postreceptor stimulus-coupling cascades are not 
mutually exclusive, and pivotal integrated cellular con­
trol is mediated via a triangle of second messengers, 
namely C a 2 + , cyclic AMP, and inositol 1,4,5 trisphos-
phate. Available evidence from studies on erythrocytes 
and platelets in animal and human models of hyperten­
sion point to the involvement of the phosphoinosi­
tides. 3 5" 3 9 Similar investigations of smooth muscle cells, 
which exhibit many more blood pressure regulating 
hormone receptors than the platelets or erythrocytes, 
are necessary. The relationship between alterations in 
phosphoinositide metabolism and membrane-asso­
ciated biochemical processes requires definition in order 
to assign causative or consequential roles in the patho­
genesis of hypertension. 
C a 2 + AND CYCLIC NUCLEOTIDES 
Cyclic nucleotides are involved in the regulation of 
heart contractility, vascular smooth muscle tone, release 
and action of catecholamines, and control of renin se­
cretion. 4 0 Most functions are regulated (either synergis-
tically or antagonistically) by C a 2 + and cyclic AMP. 4 0 
Accordingly, the finding of several anomalies in cyclic 
nucleotide metabolism in SHR and EHT is not 
surprising, 4 1" 4 3 although many of the findings are quali­
tatively discrepant. 
Of particular interest is adenylate cyclase, a mem­
brane-bound enzyme that regulates the synthesis of cy­
clic AMP via stimulatory (N8) or inhibitory (NJ guanine 
nucleotide-binding proteins. 4 4 Nâ is regulated by pro­
tein kinase C, a Ca 2 +-activated, diacylglycerol-modu-
lated enzyme. 2 9 ' 4 5 Adenylate cyclase can also be acti­
vated by calmodulin and low concentrations of C a 2 + 
( > 0.8 μΜ) in many cells, including platelets and smooth 
muscle; higher C a 2 + concentrations are inhibitory.4 6-4 7 
Cyclic AMP in turn may influence [ C a 2 + ] i by promoting 
C a 2 + efflux/sequestration. 4 0 4 8 Thus, derangements in 
either phosphoinositide, C a 2 + , and/or cyclic AMP me­
tabolism may be expected to have profound and mani­
fold effects on cell function. 
CONCLUDING REMARKS 
In the past few years our studies on alterations in cal­
cium and cyclic nucleotide metabolism in EHT have 
been confined to platelets. The complexities of both cel­
lular C a 2 + control and coordinated second-messenger 
regulation of cellular function make it difficult to assign 
causative or consequential roles to deranged platelet 
Ca 2 +-linked processes in the pathophysiology of essen­
tial hypertension. Nevertheless, our studies support an 
underlying membrane pathology as being causative be­
cause all the derangements described above— 
potential, Ca 2 + -ATPase, hormone responsiveness, 
adenylate cyclase, and event cytosolic [Ca 2 +]i 
concentrations — are membrane-associated systems. 
Modifications of phosphoinositide metabolism may be a 
key factor accounting for the multifaceted membrane 
abnormalities associated with EHT. The studies need to 
be extended to the smooth muscle cell itself to determine 
whether similar abnormalities are present in the vascu­
lature and relevant to elevated peripheral vascular re­
sistance in hypertension. 
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